Prognostic Value of Platelet to Lymphocyte Ratio for Myocardial Infarction: A Systematic Review and Meta-Analysis

IF 2.3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Clinical Cardiology Pub Date : 2025-10-14 DOI:10.1002/clc.70215

Hengxu Yu, Shitao Li, Yutong Wu, Xiangpeng Ren

{"title":"Prognostic Value of Platelet to Lymphocyte Ratio for Myocardial Infarction: A Systematic Review and Meta-Analysis","authors":"Hengxu Yu, Shitao Li, Yutong Wu, Xiangpeng Ren","doi":"10.1002/clc.70215","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Correlations between platelet-to-lymphocyte ratio (PLR) and prognosis in patients with acute myocardial infarction (AMI) are reported in more studies, though there is no evidence-based data.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Databases (PubMed, Embase, Web of Science, and Cochrane Library) were searched from their inception to April 19, 2024, to retrieve articles discussing associations between PLR and clinical outcomes in AMI patients. The primary outcomes, comprising mortality and major adverse cardiovascular events (MACE), were assessed with odds ratios (OR) and their 95% confidence intervals (CI). Sensitivity analyses and subgroup analyses were utilized to probe the results' robustness and potential heterogeneity sources. Analysis was carried out utilizing the software of Review Manager 5.4 & STATA 15.0.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>This article selected 18 cohort studies, covering 16,545 AMI patients. The meta-analysis found that elevated PLR was significantly linked with mortality in AMI patients (OR = 1.06; 95% CI: 1.04–1.08, <i>p</i> < 0.00001). Additionally, PLR was highly linked with MACE risks in AMI patients (OR = 1.495; 95% CI: 1.24–1.80, <i>p</i> < 0.0001). Further subgroup analyses discovered a significant correlation between PLR and mortality in prospective studies (OR = 1.07; 95% CI: 1.05–1.09), studies with a sample size ≥ 500 (OR = 1.06; 95% CI: 1.04–1.08), patients under 70 years of age (OR = 1.07; 95% CI: 1.05–1.09), studies from European regions (OR = 1.08; 95% CI: 1.06–1.10), patients with ST-elevation myocardial infarction (OR = 1.09; 95% CI: 1.07–1.11), and those with a PLR cutoff value < 140 (OR = 1.07; 95% CI: 1.05–1.09) (<i>p</i> < 0.05). For MACE, similar subgroup analyses also proved an obvious correlation between PLR and MACE in the aforementioned subgroups (<i>p</i> < 0.05).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>PLR values are linked with mortality and MACE in AMI patients. PLR serves as an effective prognostic biomarker for AMI patients, providing precious opinions for sensible therapeutic decisions in AMI treatments.</p>\n </section>\n </div>","PeriodicalId":10201,"journal":{"name":"Clinical Cardiology","volume":"48 10","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12520137/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Cardiology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clc.70215","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Correlations between platelet-to-lymphocyte ratio (PLR) and prognosis in patients with acute myocardial infarction (AMI) are reported in more studies, though there is no evidence-based data.

Methods

Databases (PubMed, Embase, Web of Science, and Cochrane Library) were searched from their inception to April 19, 2024, to retrieve articles discussing associations between PLR and clinical outcomes in AMI patients. The primary outcomes, comprising mortality and major adverse cardiovascular events (MACE), were assessed with odds ratios (OR) and their 95% confidence intervals (CI). Sensitivity analyses and subgroup analyses were utilized to probe the results' robustness and potential heterogeneity sources. Analysis was carried out utilizing the software of Review Manager 5.4 & STATA 15.0.

Results

This article selected 18 cohort studies, covering 16,545 AMI patients. The meta-analysis found that elevated PLR was significantly linked with mortality in AMI patients (OR = 1.06; 95% CI: 1.04–1.08, p < 0.00001). Additionally, PLR was highly linked with MACE risks in AMI patients (OR = 1.495; 95% CI: 1.24–1.80, p < 0.0001). Further subgroup analyses discovered a significant correlation between PLR and mortality in prospective studies (OR = 1.07; 95% CI: 1.05–1.09), studies with a sample size ≥ 500 (OR = 1.06; 95% CI: 1.04–1.08), patients under 70 years of age (OR = 1.07; 95% CI: 1.05–1.09), studies from European regions (OR = 1.08; 95% CI: 1.06–1.10), patients with ST-elevation myocardial infarction (OR = 1.09; 95% CI: 1.07–1.11), and those with a PLR cutoff value < 140 (OR = 1.07; 95% CI: 1.05–1.09) (p < 0.05). For MACE, similar subgroup analyses also proved an obvious correlation between PLR and MACE in the aforementioned subgroups (p < 0.05).

Conclusion

PLR values are linked with mortality and MACE in AMI patients. PLR serves as an effective prognostic biomarker for AMI patients, providing precious opinions for sensible therapeutic decisions in AMI treatments.

Abstract Image

查看原文本刊更多论文

血小板/淋巴细胞比值对心肌梗死的预后价值：一项系统综述和荟萃分析。

背景：急性心肌梗死（AMI）患者的血小板与淋巴细胞比率（PLR）与预后之间的相关性被更多的研究报道，尽管没有基于证据的数据。方法：检索数据库（PubMed、Embase、Web of Science和Cochrane Library），检索从数据库建立到2024年4月19日讨论AMI患者PLR与临床结局之间关系的文章。主要结局包括死亡率和主要不良心血管事件（MACE），采用优势比（OR）及其95%置信区间（CI）进行评估。采用敏感性分析和亚组分析来探讨结果的稳健性和潜在异质性来源。利用Review Manager 5.4和STATA 15.0软件进行分析。结果：本文选择了18项队列研究，涵盖了16545例AMI患者。荟萃分析发现，AMI患者PLR升高与死亡率显著相关（OR = 1.06; 95% CI: 1.04-1.08, p）。结论：AMI患者PLR值与死亡率和MACE相关。PLR作为AMI患者有效的预后生物标志物，为AMI治疗的合理治疗决策提供宝贵意见。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Cardiology 医学-心血管系统

CiteScore

5.10

自引率

3.70%

发文量

189

审稿时长

4-8 weeks

期刊介绍： Clinical Cardiology provides a fully Gold Open Access forum for the publication of original clinical research, as well as brief reviews of diagnostic and therapeutic issues in cardiovascular medicine and cardiovascular surgery. The journal includes Clinical Investigations, Reviews, free standing editorials and commentaries, and bonus online-only content. The journal also publishes supplements, Expert Panel Discussions, sponsored clinical Reviews, Trial Designs, and Quality and Outcomes.